What dose of Cosentyx (secukinumab) is used for psoriatic arthritis?
For psoriatic arthritis, Cosentyx dosing is the same as the labeled dosing used across the condition and is given by subcutaneous injection. The regimen starts with loading doses, then continues with maintenance dosing.
Typical labeled schedule:
- Loading: 150 mg once weekly for 5 weeks (weeks 0, 1, 2, 3, and 4)
- Maintenance: 150 mg every 4 weeks starting at week 8
Some patients may be prescribed 300 mg maintenance based on clinical need, using the same general weekly-to-monthly schedule.
Can Cosentyx be dosed at 300 mg for psoriatic arthritis?
Yes. Cosentyx has a higher-dose option (300 mg) that is sometimes used in psoriatic arthritis when clinicians determine it’s appropriate based on disease severity and response. The higher dose is typically used as a maintenance dose rather than as the standard starter approach.
How is Cosentyx given (injection schedule and timing)?
Cosentyx is injected under the skin. The dosing schedule follows the loading phase first, then switches to every-4-weeks maintenance dosing. If you miss a dose, the next dose is generally taken as soon as possible and then the original schedule is resumed, but the exact instructions depend on how far along you are in the course.
Does Cosentyx dosing differ for psoriatic arthritis with other conditions?
The psoriatic arthritis dosing schedule itself is based on the condition and the selected dose (150 mg vs 300 mg). The presence of other diseases (such as plaque psoriasis) can affect which Cosentyx strength or schedule is used overall, but for psoriatic arthritis the drug uses the loading/maintenance structure described above.
What should patients monitor while on Cosentyx?
Patients are commonly advised to watch for signs of infection, including fever or symptoms that suggest an infection, since secukinumab suppresses parts of the immune response (IL-17A pathway). If you develop concerning symptoms, contact the prescribing clinician promptly.
Sources
- DrugPatentWatch.com (Cosentyx/secukinumab dosing and related product/regulatory information): https://www.drugpatentwatch.com/